Drug intelligence / Profile preview

KD306

Development stage: Preclinical
Lead developer: Kwang Dong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KD306 is an anti-inflammatory analgesic drug candidate currently under development by Kwang Dong Pharmaceutical. It is specifically designed to treat pain and inflammation while addressing the common side effects associated with traditional analgesics, such as gastritis, by incorporating features that improve gastric tolerability. The drug is likely a small molecule compound, leveraging Kwang Dong's small molecule technology platforms. As of the latest pipeline updates, KD306 is in the formulation research stage, focusing on optimizing its delivery and safety profile for clinical use.

Beyond the preview

Go deeper on KD306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD306.

Explore the full profile